logo-loader
viewRedx Pharma PLC

Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased investment by Redmile

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has increased its stake to 91.76% from 58.25%.

Quick facts: Redx Pharma PLC

Price: 35 GBX

AIM:REDX
Market: AIM
Market Cap: £66.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma 'on a firm footing and able to drive its business plan'...

Redx Pharma PLC's (LON:REDX) Lisa Anson caught up with Proactive London's Andrew Scott after announcing they've raised US$30mln via the issue of convertible loan notes. Funds Redmile Group and Sofinnova Partners are putting up US$19mln and US$10mln respectively. The cash will be used to...

6 days, 8 hours ago

2 min read